Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.76USD
4:00pm EDT
Change (% chg)

$-0.12 (-6.38%)
Prev Close
$1.88
Open
$1.85
Day's High
$1.85
Day's Low
$1.76
Volume
6,650
Avg. Vol
25,437
52-wk High
$11.90
52-wk Low
$1.71

Latest Key Developments (Source: Significant Developments)

Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful
Friday, 8 Dec 2017 04:05pm EST 

Dec 8 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT.AKARI THERAPEUTICS PLC - NEW DOSING REGIMEN AT 45 MG PER DAY IS EXPECTED TO BE USED IN PHASE III TRIALS.AKARI - PLANS TO COMMENCE TWO PHASE III PNH CLINICAL TRIALS WITH COVERSIN BEGINNING WITH CAPSTONE IN Q1 OF 2018.AKARI THERAPEUTICS PLC - ON TRACK TO PROGRESS INTO PHASE III CLINICAL TRIALS IN Q1 OF 2018.AKARI THERAPEUTICS PLC - SECOND PHASE III TRIAL, ASSET, IS PLANNED FOR H2 2018 & WILL INCLUDE SOLIRIS SWITCH PATIENTS.  Full Article

Akari Therapeutics says priced public offering of american depositary shares
Wednesday, 18 Oct 2017 09:00am EDT 

Oct 18 (Reuters) - Akari Therapeutics Plc :Akari therapeutics announces pricing of public offering of american depositary shares.Akari therapeutics plc - priced public offering of 3.5 million american depositary shares, or adss, at $5.00 per ads​.  Full Article

Akari Therapeutics appoints David Horn Solomon as CEO
Monday, 21 Aug 2017 07:05am EDT 

Aug 21 (Reuters) - Akari Therapeutics Plc ::Akari Therapeutics announces appointment of David Horn Solomon as CEO.Says Dr David Horn Solomon appointed CEO.Akari Therapeutics Plc - ‍david Horn Solomon will be appointed as company's new chief executive officer effective August 28​.  Full Article

Akari Therapeutics PLC files for mixed shelf of up to $100 mln
Friday, 18 Aug 2017 05:11pm EDT 

Aug 18 (Reuters) - Akari Therapeutics PLC :Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing.  Full Article

Akari Therapeutics says Roshwalb submitted resignation as CEO and member of board - SEC Filing‍​
Tuesday, 30 May 2017 05:59pm EDT 

May 30 (Reuters) - Akari Therapeutics Plc : :On May 29, Roshwalb submitted resignation as CEO and member of the company’s board of directors, effective immediately ‍​.Company has commenced an executive search to identify a replacement chief executive officer -SEC filing.In the interim, Ray Prudo will continue to act as the company’s chief executive officer‍​.On May 12, putative class action was filed in court against co , co's chief executive officer and co's chief financial officer.Announces data correction for fifth patient in Phase 2 Pnh trial for Coversin.Says previously reported interim analysis of ongoing Phase 2 pnh trial of Coversin was inaccurate with respect to information for 1 of 5 patients.On may 19, another putative class action filed in court against co,co's chief executive officer, co's chief financial officer.Found that the patient, who was withdrawn from trial due to a suspected co-morbidity unrelated to treatment, did not meet primary endpoint.Plaintiffs in both class actions asserted claims alleging "federal securities laws violations" relating to co's press release on April 27.Plaintiffs allege "federal securities laws violations" relating to co's press release on april 27 on Edison report .Expects to release additional results with respect to 4 continuing patients in Phase 2 pnh trial of Coversin in about 4 weeks‍​‍​.Class actions seek unspecified damages and costs and fees.  Full Article

Akari Therapeutics says CEO Gur Roshwalb has been placed on administrative leave
Thursday, 11 May 2017 04:14pm EDT 

May 11 (Reuters) - Akari Therapeutics Plc :Akari Therapeutics says Gur Roshwalb, CEO, has been placed on administrative leave - sec filing.Akari Therapeutics says Ray Prudo in his role as executive chairman is temporarily assuming Roshwalb’S duties in his absence.Akari Therapeutics - board has established ad hoc special committee to review involvement, if any, of co personnel with Edison investment research report.  Full Article

Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial
Monday, 24 Apr 2017 07:15am EDT 

April 24 (Reuters) - Akari Therapeutics Plc ::Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial and in additional clinical targets.Akari Therapeutics Plc - new preclinical data demonstrates positive response of coversin's combined c5 and ltb4 therapy in skin and eye models.Akari Therapeutics Plc - phase 3 PNH program expected to commence in 4q2017.Akari Therapeutics Plc - phase 2 programs in mucous membrane pemphigoid (eye) and bullous pemphigoid (skin) expected to commence in 1q2018.Akari Therapeutics Plc- expects to initiate its phase 2 trial in AHUS in 2Q2017, and anticipates phase 2 ahus data 2Q2018..Akari Therapeutics Plc - anticipates initial phase 3 data for PNH in 1q2019.  Full Article

Akari Therapeutics announces FDA fast track designation for Coversin
Thursday, 30 Mar 2017 04:02pm EDT 

Akari Therapeutics Plc : Akari Therapeutics announces FDA fast track designation for Coversin .Akari Therapeutics Plc says is evaluating coversin in two Phase 2 clinical trials.  Full Article

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING